Insmed (NASDAQ:INSM) Rating Lowered to Hold at ValuEngine
INSM has been the subject of several other research reports. Goldman Sachs Group assumed coverage on Insmed in a report on Tuesday, September 3rd. They set a buy rating and a $30.00 price target for the company. BidaskClub raised Insmed from a sell rating to a hold rating in a report on Monday, November 25th. Credit Suisse Group reiterated a buy rating and set a $40.00 target price on shares of Insmed in a research report on Tuesday, September 10th. Zacks Investment Research lowered shares of Insmed from a buy rating to a hold rating in a report on Friday, September 27th. Finally, HC Wainwright restated a buy rating on shares of Insmed in a research report on Thursday, October 31st. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $37.86.
INSM opened at $23.10 on Thursday. The company has a market capitalization of $2.02 billion, a PE ratio of -5.54 and a beta of 3.04. The firm has a 50-day simple moving average of $19.99 and a two-hundred day simple moving average of $20.60. The company has a quick ratio of 6.70, a current ratio of 6.97 and a debt-to-equity ratio of 1.19. Insmed has a 52 week low of $11.31 and a 52 week high of $33.13.
In related news, CAO John Goll sold 25,000 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $20.80, for a total value of $520,000.00. 4.95% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 Hong Kong Ltd bought a new stake in Insmed in the second quarter worth $34,000. Riverhead Capital Management LLC purchased a new stake in shares of Insmed in the second quarter valued at $73,000. NumerixS Investment Technologies Inc raised its stake in shares of Insmed by 26.5% in the second quarter. NumerixS Investment Technologies Inc now owns 4,807 shares of the biopharmaceutical company’s stock valued at $123,000 after acquiring an additional 1,007 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Insmed by 17.2% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,818 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 854 shares during the period. Finally, Tyers Asset Management LLC lifted its holdings in shares of Insmed by 1,002.5% in the 2nd quarter. Tyers Asset Management LLC now owns 7,056 shares of the biopharmaceutical company’s stock worth $181,000 after acquiring an additional 6,416 shares during the last quarter.
Insmed Company Profile
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Featured Article: What is a Lock-Up Period?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.